Leukocyte-nanomedicine system for targeted delivery and precise theragnostics

Targeted delivery of nanomedicines to disease sites via living cell carriers has attracted extensive attention, but a better way to direct nanomedicines to carriers is still under exploration. Recently in Nature Nanotechnology, Cruz et al. modified the binding peptides on nanomedicines to hitchhike with specifically activated leukocytes for improved therapy of venous thrombosis.